Viking's Cash and Short-Term Investments Drop to $706M
At December 31, 2025, Viking held cash, cash equivalents and short-term investments of $706M, compared to $903 M as of December 31, 2024. "The past year was an exceptional year for Viking marked by rapid progress across our obesity portfolio," stated Brian Lian, Ph.D., CEO of Viking. "In June, the company initiated the Phase 3 VANQUISH clinical program evaluating the subcutaneous formulation of VK2735, a dual agonist of the GLP-1 and GIP receptors, for obesity. We announced completion of enrollment in VANQUISH-1 in the fourth quarter and expect to complete enrollment in VANQUISH-2 later this quarter. In 2025 the company also announced positive top-line results from its Phase 2 VENTURE-Oral dosing trial of the tablet formulation of VK2735 in obesity. Following feedback from an end-of-Phase 2 meeting with the FDA, we plan to advance oral VK2735 into Phase 3 development in 3Q26. Based on exciting early data suggesting the potential for maintenance dosing with VK2735, in the fourth quarter we initiated a study designed to evaluate monthly subcutaneous dosing, daily oral dosing, and weekly oral dosing. This trial will provide data to potentially further differentiate VK2735 as the only dual agonist molecule with the potential to dose monthly or to allow transition from subcutaneous to oral administration for weight maintenance. This study is fully enrolled and we look forward to announcing the results in the third quarter of 2026. We also expect to file an IND for our novel amylin agonist this quarter, expanding our obesity franchise. During the year Viking continued building the foundation to support commercial activities by entering into a comprehensive manufacturing and supply agreement for VK2735 and expanding our commercial depth to prepare for success. Throughout these activities we have continued to exercise fiscal discipline and maintain a strong balance sheet, which will allow us to meet key milestones in the quarters ahead. We expect 2026 to be another exciting and productive year and look forward to providing updates along the way."
